Curis, Inc. (NASDAQ:CRIS) has been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $24.33.
Several brokerages have recently commented on CRIS. Zacks Investment Research upgraded Curis from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research report on Wednesday, August 8th. Cowen reiterated a “buy” rating on shares of Curis in a research report on Monday, August 6th. ValuEngine lowered Curis from a “buy” rating to a “hold” rating in a research report on Monday, July 2nd. Finally, SunTrust Banks decreased their target price on Curis to $8.00 and set a “buy” rating for the company in a research report on Friday, August 3rd.
A number of hedge funds have recently made changes to their positions in CRIS. Candriam Luxembourg S.C.A. acquired a new position in Curis during the 1st quarter worth $523,000. GSA Capital Partners LLP boosted its position in Curis by 104.2% during the 1st quarter. GSA Capital Partners LLP now owns 1,913,208 shares of the biotechnology company’s stock worth $1,250,000 after acquiring an additional 976,151 shares during the period. Arnhold LLC acquired a new position in Curis during the 1st quarter worth $1,907,000. Sio Capital Management LLC acquired a new position in Curis during the 1st quarter worth $545,000. Finally, LMR Partners LLP acquired a new position in Curis during the 2nd quarter worth $124,000. Institutional investors own 33.49% of the company’s stock.
Curis (NASDAQ:CRIS) last posted its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.15. Curis had a negative return on equity of 225.77% and a negative net margin of 407.29%. The company had revenue of $2.36 million for the quarter, compared to the consensus estimate of $2.41 million. equities analysts forecast that Curis will post -1.18 EPS for the current fiscal year.
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
Read More: Penny Stocks
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.